# BRCA1/2 in pancreatic cancer

1 EU-approved indication in pancreatic cancer needs a BRCA1/2 result: olaparib (maintenance, metastatic).

## Approved indications

### BRCA1/2 mutation

| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| [Olaparib](https://oncolabels.com/drugs/olaparib) (Lynparza) | Germline BRCA1/2 mutation | Monotherapy | Maintenance, metastatic | After minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen without progression |

## Label wording

- **Olaparib** (Lynparza), Pancreatic cancer, maintenance, metastatic: “monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf)

Source: section 4.1 of each summary of product characteristics (SmPC), EMA data as of 5 Nov 2026. AI models structured these entries and no person has checked them yet. oncolabels is a non-commercial reference for education and research and gives no medical advice; the current SmPC takes precedence.

Data under CC BY 4.0: credit oncolabels and the European Medicines Agency. Page: https://oncolabels.com/tumours/pancreatic-cancer/brca1-2